Evidence map›Paper›PMID 39516657›Full record

ArticleOncogene2025

Enhancing low-dose radiotherapy efficacy with PARP inhibitors via FBL-mediated oxidative stress response in colorectal cancer.

Ming Wen, Yanfang Qiu, Meng Wang, Feiyu Tang, Wenfeng Hu, Yongwei Zhu, Wenchao Zhao, Wenzhen Hu, Zhuohang Chen, Yumei Duan and 9 more

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. NJournal of bioenergetics and biomembranes · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ming Wen *Department of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yanfang Qiu *Department of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Meng WangDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Feiyu TangDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Wenfeng HuDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yongwei ZhuHunan International Scientific and Technological Cooperation Base of Brain Tumor Research, Xiangya Hospital, Central South University, Changsha, 410008, China.
Wenchao ZhaoDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Wenzhen HuDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhuohang ChenDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yumei DuanDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Anke GengShanghai Key Laboratory of Maternal Fetal Medicine, Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Fengbo TanGeneral Surgery Department, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yuqiang LiGeneral Surgery Department, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qian PeiGeneral Surgery Department, Xiangya Hospital, Central South University, Changsha, 410008, China.
Haiping PeiGeneral Surgery Department, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhiyong MaoShanghai Key Laboratory of Maternal Fetal Medicine, Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.ORCID http://orcid.org/0000-0002-5298-1918
Ningbo WuShanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Lunquan SunDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China. lunquansun@csu.edu.cn.ORCID http://orcid.org/0000-0002-0558-5250
Rong TanDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China. rongtan@csu.edu.cn.ORCID http://orcid.org/0000-0002-3629-8668

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81702956National Natural Science Foundation of China (National Science Foundation of China) 81902888National Natural Science Foundation of China (National Science Foundation of China) 81974451National Natural Science Foundation of China (National Science Foundation of China) 82030087
6 · The paper itself

Abstract

The effectiveness of radiotherapy in colorectal cancer (CRC) relies on its ability to induce cell death via the generation of reactive oxygen species (ROS). However, genes responsible for mitigating oxidative stress can impede radiotherapy's efficacy. In this study, we elucidate a significant association between the nucleolar protein Fibrillarin (FBL) and the oxidative stress response in CRC tumors. Our findings reveal elevated expression of FBL in colorectal cancer, which positively correlates with oxidative stress levels. Mechanistically, FBL demonstrates direct accumulation at DNA damage sites under the regulation of PARP1. Specifically, the N-terminal GAR domain of FBL is susceptible to PARylation by PARP1, enabling FBL to recognize PARylated proteins. The accumulation of damaged FBL plays a pivotal role in facilitating short-patched base excision repair by recruiting Ligase III and disassociating PCNA and FEN1. Moreover, tumors with heightened FBL expression exhibit reduced DNA damage levels but increased sensitivity to combined low-dose radiotherapy and olaparib treatment. This underscores the potential of leveraging PARP inhibitors to augment radiotherapy sensitivity in CRC cases characterized by elevated FBL expression, offering a promising therapeutic avenue.

Indexed as

Chromosomal Proteins, Non-HistoneColorectal NeoplasmsOxidative StressPoly(ADP-ribose) Polymerase InhibitorsAnimalsCell Line, TumorDNA DamageDNA RepairFemaleHumansMicePhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Reactive Oxygen SpeciesChromosomal Proteins, Non-HistoneolaparibPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsReactive Oxygen Species

Identifiers

PMID39516657
PMCPMC11746129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.